摘要
目前研究发现环氧化酶-2(COX-2)与乳腺癌的发生有密切联系。COX-2及其催化产物前列腺素(PGs)参与炎症的多种过程,且可通过多种致病机制参与多种实体瘤的发生、发展过程。塞来昔布作为新型非甾体类抗炎药(NASIDs),是一种高选择性的COX-2抑制剂,国内外的研究表明,其对上皮组织癌有一定的抑制作用。该文就塞来昔布抗乳腺癌的机制及其临床研究进行了综述。
The recent researches show that cyclooxygenase-2（COX-2） has a close connection to the occurrence of breast cancer. COX-2 and its catalysate prostaglandins（PGs） not only participate in the multiple processes of inflammation, but also involve in the occurrence and development processes of multiple solid tumors. Celecoxib as a new type non- steroid anti- inflammatory drug is a highly selective COX- 2 inhibitor. The reports at home and abroad indicate that celecoxib has certain inhibiting effect on epithelial carcinoma. This article reviews the celecoxib＇s anti- breast cancer mechanism and clinical researches.
出处
《中国药业》
CAS
2013年第23期1-3,共3页
China Pharmaceuticals
作者简介
余文韬（1987-）,硕士研究生,药师,（电话）028-85420311（电子信箱）64187564@qq.com｜
蒋刚（1964-）,大学本科,主任药师,本文通讯作者,（电话）028-85420338（电子信箱）13931963379@163.com.
